1. Generics Bulletin
  2. >>Business
  3. >>Strategy

Samsung Bioepis’ Ko Insists On Value Of Data

Real-World Evidence Is Essential In Bolstering Biosimilars

 
• By Dave Wallace

In the third and final part of an exclusive interview with Generics Bulletin, Samsung Bioepis CEO Christopher Hansung Ko talks about the importance of real-world data in bolstering biosimilars, as well as outlining the firm’s future pipeline.

Doctor_Hand_Screen
Real-world data is key to build confidence in biosimilars, Ko says • Source: Shutterstock

As CEO of the Samsung Bioepis joint venture between Samsung BioLogics and Biogen, Christopher Hansung Ko oversees a major player in the global biosimilars market.

In the first two parts of this exclusive interview, Ko discussed Samsung Bioepis’ interests in the US (Also see "

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Hikma Rides Price Gap as Novo’s Ozempic, Wegovy Costs Climb

 
• By Dean Rudge

Hikma is seeing increased US demand for its generic Victoza (liraglutide) after the end of semaglutide compounding lifted prices for Novo Nordisk’s Ozempic and Wegovy. Meanwhile, the company is not for now pursuing semaglutide generics in the US or EU due to patent protection, but is targeting MENA.

Iron Sucrose Competition Expands With Viatris and Amphastar FDA Approvals

 
• By Dean Rudge

Viatris and Amphastar are expanding their complex generic portfolios with the planned launches of FDA-approved versions of Vifor Pharma/Daiichi Sankyo’s Venofer (iron sucrose). The FDA’s database also show Sandoz holds an approval for generic Venofer, though it has not disclosed launch plans.

Amgen Welcomes Evolving Biosimilar Guidelines As Competitive Advantage

 
• By Dean Rudge

Amgen sees potential regulatory shifts toward streamlined biosimilar approvals as favorable, citing its strength in developing high-quality products.

Repurposed Generics For Rare Diseases: Janet Woodcock Proposes Shortcut

A Duke-Margolis working group is developing ideas to enable non-profit firms to seek US FDA approval for new indications for off-patent medicines. The former acting commissioner thinks citizen petitions might be the fastest route.

More from Business

Amgen Welcomes Evolving Biosimilar Guidelines As Competitive Advantage

 
• By Dean Rudge

Amgen sees potential regulatory shifts toward streamlined biosimilar approvals as favorable, citing its strength in developing high-quality products.

‘Made-In-America’ Amneal Does Not Fear Trump’s Proposed ‘Chaotic’ Triple-Digit Tariffs On Drugs

 
• By Urtė Fultinavičiūtė

As Amneal reports another solid quarterly performance, with refinanced debt and adjusted financial guidance for the year, will Trump’s “chaotic” tariffs shake it all up?

Repurposed Generics For Rare Diseases: Janet Woodcock Proposes Shortcut

A Duke-Margolis working group is developing ideas to enable non-profit firms to seek US FDA approval for new indications for off-patent medicines. The former acting commissioner thinks citizen petitions might be the fastest route.